Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 MPN-associated myelofibrosis (MPN-MF).

Literature DB >> 20684988

MPN-associated myelofibrosis (MPN-MF).

R A Mesa¹, A Green, G Barosi, S Verstovsek, J Vardiman, R P Gale.

Abstract

Entities: Disease

Mesh：

Year: 2010 PMID： 20684988 DOI： 10.1016/j.leukres.2010.07.019

Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156

Keyword Cloud
Cited

× No keyword cloud information.

29 in total

Review 1. Management of myeloproliferative neoplasms: from academic guidelines to clinical practice.

Authors: Giovanni Barosi; Letizia Lupo; Vittorio Rosti
Journal: Curr Hematol Malig Rep Date: 2012-03 Impact factor: 3.952

2. A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis.

Authors: Kenji Oritani; Shinichiro Okamoto; Tetsuzo Tauchi; Shigeki Saito; Kohshi Ohishi; Hiroshi Handa; Katsuto Takenaka; Prashanth Gopalakrishna; Taro Amagasaki; Kazuo Ito; Koichi Akashi
Journal: Int J Hematol Date: 2015-02-01 Impact factor: 2.490

3. JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.

Authors: Alessandro M Vannucchi; Lisa Pieri; Paola Guglielmelli
Journal: Ther Adv Hematol Date: 2011-02

Review 4. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.

Authors: N M Kröger; J H Deeg; E Olavarria; D Niederwieser; A Bacigalupo; T Barbui; A Rambaldi; R Mesa; A Tefferi; M Griesshammer; V Gupta; C Harrison; H Alchalby; A M Vannucchi; F Cervantes; M Robin; M Ditschkowski; V Fauble; D McLornan; K Ballen; U R Popat; F Passamonti; D Rondelli; G Barosi
Journal: Leukemia Date: 2015-08-21 Impact factor: 11.528

5. Which clinical significance has automatic detection of very low levels of nucleated red blood cells in the peripheral blood?

Authors: Sabrina Buoro; Barbara Manenti; Michela Seghezzi
Journal: Ann Transl Med Date: 2016-06

6. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.

Authors: Vikas Gupta; Claire Harrison; Elizabeth O Hexner; Haifa Kathrin Al-Ali; Lynda Foltz; Michael Montgomery; William Sun; Prashanth Gopalakrishna; Hagop Kantarjian; Srdan Verstovsek
Journal: Haematologica Date: 2016-09-01 Impact factor: 9.941

MPN-associated myelofibrosis (MPN-MF).

Review 1. Management of myeloproliferative neoplasms: from academic guidelines to clinical practice.

2. A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis.

3. JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.

Review 4. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.

5. Which clinical significance has automatic detection of very low levels of nucleated red blood cells in the peripheral blood?

6. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.

7. Low-dose ruxolitinib shows effective in treating myelofibrosis.

Review 8. Ruxolitinib dose management as a key to long-term treatment success.

Review 9. Ruxolitinib for myelofibrosis--an update of its clinical effects.

Review 10. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.